Year archive

Lonza Group AG — 2022 filings

All 13 regulatory filings released by Lonza Group AG (LONN) in 2022, sourced directly from the official regulator.

13 Filings

2022 Period

2022 filings (13)

Filing	Released	Lang
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine Regulatory Filings	2022-11-01	English
Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine Regulatory Filings	2022-11-01	English
Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division Board/Management Information	2022-09-12	English
Lonza and Touchlight collaborate on end-to-end mRNA offering Regulatory Filings	2022-09-06	English
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin Earnings Release H1 2022	2022-07-22	English
Lonza Delivers Solid Performance in H1 2022 with 16.8% CER Sales Growth and 33.1% CORE EBITDA Margin Earnings Release H1 2022	2022-07-22	English
Lonza erzielt im ersten Halbjahr 2022 ein solides Ergebnis mit einem Umsatzwachstum von 16.8% (kWk) und einer Kern-EBITDA-Marge von 33.1% Earnings Release H1 2022	2022-07-22	German
Maria Soler Nunez appointed as Head, Group Operations Board/Management Information	2022-07-01	English
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH) Regulatory Filings	2022-07-01	English
Lonza to Establish Large-Scale, Commercial Drug Product Fill & Finish Facility in Stein (CH) M&A Activity	2022-07-01	English
Maria Soler Nunez appointed as Head, Group Operations Board/Management Information	2022-07-01	English
Lonza erzielt ein starkes Ergebnis in 2021 mit 20% Umsatzwachstum (kWk) Earnings Release FY 2021	2022-01-26	German
Lonza Delivers Strong 2021 performance with 20% CER Sales Growth Earnings Release FY 2021	2022-01-26	English